How should a patient with sensory‑motor axonal neuropathy be evaluated and managed?

Evaluation and Management of Sensory-Motor Axonal Neuropathy

Begin with a targeted laboratory workup to identify treatable causes: fasting glucose or HbA1c, vitamin B12 with methylmalonic acid, serum protein immunofixation electrophoresis, TSH, comprehensive metabolic panel, and HIV serology when risk factors exist. 1

Initial Diagnostic Evaluation

Essential Laboratory Tests

• Metabolic screening: Fasting blood glucose or HbA1c detects diabetes; if borderline, perform glucose tolerance test since 25–36% of idiopathic sensory neuropathy cases have impaired glucose tolerance 1
• Vitamin deficiencies: Vitamin B12 with methylmalonic acid (± homocysteine) identifies reversible B12 deficiency 1
• Monoclonal gammopathy: Serum protein immunofixation electrophoresis detects monoclonal proteins in ≈10% of otherwise unexplained cases 1
• Thyroid function: TSH measurement excludes hypothyroidism 1
• Renal function: Comprehensive metabolic panel identifies uremic neuropathy 1
• Infectious causes: HIV serology when risk factors present 1

Electrodiagnostic Studies

• Nerve conduction studies (NCS) and EMG confirm axonal neuropathy pattern: reduced compound muscle action potential and sensory nerve action potential amplitudes with marginal slowing of conduction velocity 2, 3
• Electrophysiological testing is rarely needed for typical distal symmetric polyneuropathy but essential when clinical features are atypical (asymmetric distribution, rapid progression, motor predominance) 4

When to Refer for Advanced Testing

• Neurology referral indicated for atypical features: asymmetric involvement, rapid progression, predominant motor weakness, or suspected hereditary neuropathy 1
• Skin biopsy with intraepidermal nerve fiber density assessment confirms small fiber neuropathy when large fiber testing is normal 5, 1
• Combined nerve and muscle biopsy over nerve biopsy alone when vasculitis or inflammatory neuropathy suspected 6, 7

Pharmacologic Pain Management

First-Line Agents (Select Based on Comorbidities)

Duloxetine is the preferred initial choice for most patients: start 60 mg daily, titrate to 120 mg as needed; FDA-approved for diabetic neuropathy with 38% achieving ≥50% pain reduction; also treats comorbid depression; contraindicated in hepatic disease 4, 6, 8, 9, 5, 1

Alternative first-line options:

• Gabapentin: 300–1,200 mg three times daily, titrated slowly; requires caution in patients prone to edema or falls 4, 6, 8, 5, 1
• Pregabalin: 100 mg three times daily; FDA-approved for diabetic neuropathy; same precautions as gabapentin 4, 6, 8, 5, 1
• Tricyclic antidepressants: Nortriptyline or desipramine 25–75 mg at bedtime preferred over amitriptyline for fewer anticholinergic effects; number needed to treat 1.5–3.5; start 10 mg/day, maintain 6–8 weeks for adequate trial, maximum <100 mg/day; obtain ECG in patients >40 years; contraindicated in glaucoma, orthostatic hypotension, cardiovascular disease 4, 6, 8, 7, 5, 10, 1

Second-Line and Combination Strategies

• Combination therapy: If inadequate response after 6–8 week trial of first-line agent, add medication from different class (e.g., duloxetine plus gabapentin) 8, 10, 1
• Opioid analgesics: Tramadol 200–400 mg/day or oxycodone 20–80 mg/day reserved for severe or breakthrough pain 7, 5, 10
• Topical capsaicin: 0.025–0.075% applied 3–4 times daily for localized pain 4, 6, 7

Critical Pharmacologic Caveats

• No disease-modifying therapies exist; all medications provide symptomatic relief only and do not reverse neuronal loss 4, 6, 7, 1
• Glycemic control in diabetic patients may slow progression but does not reverse existing nerve damage 4, 11, 1
• Up to 50% of neuropathy is asymptomatic; pharmacologic treatment reserved for symptomatic patients 4, 6, 1
• Realistic treatment goals: Aim for ≥30–50% pain reduction to improve quality of life 8, 10, 1

Non-Pharmacologic Management

Foot Care Education (Essential for All Patients)

• Daily foot inspection: Visual and manual examination for ulcers, blisters, calluses 4, 11, 12, 1
• Annual monofilament testing: 10-g monofilament identifies feet at risk for ulceration and amputation 4, 11, 12, 1
• Therapeutic footwear: Well-fitted shoes for patients with increased plantar pressure or foot deformities 12, 1
• Regular podiatric care: Callus debridement and nail management 12, 1

Autonomic Neuropathy Screening

• Assess for gastroparesis: Early satiety, nausea, erratic glucose control 4, 7, 1
• Evaluate sudomotor dysfunction: Abnormal sweating patterns 13, 7, 1
• Monitor cardiovascular autonomic function: Resting tachycardia >100 bpm, orthostatic hypotension (fall in systolic or diastolic blood pressure) 11

Physical Activity

• Regular physical activity recommended for neuropathy symptom management and overall health 14, 13

Monitoring and Follow-Up

• Serial neurologic examinations preferred over repeated electromyography/nerve conduction studies (e.g., every 6 months) to monitor disease activity 6, 7
• Reassess pain and quality of life frequently; if substantial pain relief (average pain ≤3/10) with tolerable adverse effects, continue treatment 10
• If partial relief (average pain ≥4/10) after adequate trial, add second first-line medication from different class 10
• If no or inadequate relief (<30% reduction) at target dosage after adequate trial, switch to alternative first-line medication 10